Bharat Parenterals Limited Q4 FY26 earnings call summary

Earnings call of 19 May 2026, summarised by AI from the filing.

Bharat Parenterals FY26 consolidated revenue ₹345.4 cr, EBITDA ₹15.8 cr; guides FY27 standalone revenue growth 10-15%, Innoxel 35-45%.

Key takeaways

1. Growth driver Innoxel regulatory clearances (US FDA EIR, FAMHP) enable commercial supply to US and Europe from FY27.
2. Risk Disruption from PIC/S and EUGMP inspections at standalone facilities in FY27.

Original filing on BSE

Bharat Parenterals Limited earnings call, investor presentation and press release summaries

• Q1 FY27: Results deck (5 Aug 2026)
• Q4 FY26: Earnings call (19 May 2026), Results deck (18 May 2026)
• Q3 FY26: Results deck (30 Jan 2026)
• Q2 FY26: Earnings call (12 Nov 2025), Results deck (12 Nov 2025)
• Q1 FY26: Results deck (28 Jul 2025)
• Q4 FY25: Earnings call (14 May 2025)